Press Releases

26

Apr, 2022

GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections

Tags: ,

Geneva, 26 April 2022 – A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns. At the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the Global Antibiotic Research and Development Partnership (GARDP) has released a second wave of findings from its study on the outcomes of more than 3,200 newborns with neonatal sepsis, a life-threatening bloodstream infection that affects up to 3 million babies a year. The study shows that […]

READ MORE

26

Apr, 2022

Uno studio di GARDP rivela che i neonati muoiono sempre più frequentemente per sepsi neonatale causata da infezioni batteriche resistenti ai farmaci

Tags: ,

Ginevra, 26 Aprile 2022 – Un importante studio sui neonati ha rivelato l’impatto della resistenza agli antibiotici sulla sepsi neonatale, una delle principali cause di morte tra i neonati. Al Congresso europeo di microbiologia clinica e malattie infettive (ECCMID), GARDP – un partenariato internazionale per la ricerca e lo sviluppo di antibiotici (Global Antibiotic Research and Development Partnership) – ha presentato una serie di risultati provenienti da uno studio condotto su oltre 3.200 neonati con sepsi neonatale, un’infezione potenzialmente mortale. Lo studio ha rivelato che il numero di bambini che […]

READ MORE

15

Feb, 2022

European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients

Tags: ,

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                   “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA’s recombinant Covid-19 vaccine in children (including adolescents) and immunocompromised people. The trials will last 2.5 years. […]

READ MORE

28

Jun, 2021

Nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini

Tags:

Università degli Studi di Padova, Istituto Zooprofilattico Sperimentale delle Venezie e Penta presentano nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini Uno studio pubblicato in questi giorni sulla rivista “Paediatrics” dimostra che i bambini affetti da forme lievi di COVID-19 sviluppano una risposta anticorpale maggiore e più duratura di quella degli adulti. Lo studio ha coinvolto 57 famiglie venete colpite dal COVID 19 e seguite presso il Dipartimento Salute della Donna e del Bambino dell’Università di Padova.   Padova, 28 giugno 2021 – Ricercatori dell’Università degli Studi […]

READ MORE

1

Apr, 2019

GARDP and Penta partner to accelerate the development of children’s antibiotics to tackle AMR

 

Geneva / Padova, Monday 4 March 2019 – The Global Antibiotic Research & Development Partnership (GARDP) and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines. Globally, more than three million childhood deaths result from infectious diseases, such as pneumonia and sepsis (1). Children are also particularly affected by antimicrobial resistance […]

READ MORE

1

Apr, 2019

University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics

Tags: ,

Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities